Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 125
Single User License Price INR 8538
Corporate User License Price USD 375
Corporate User License Price INR 25613
Site License Price USD 250
Site License Price INR 17075
Request a Quote

Report Title

Hikma Pharmaceuticals Plc HIK-Financial and Strategic SWOT Analysis Review

Quote Request for License Type
License Type Price  
Single User License USD 125
Site License USD 250
Enterprise Wide License USD 375
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hikma Pharmaceuticals Plc HIK-Financial and Strategic SWOT Analysis Review


Quote Request for License Type
License Type Price  
Single User License USD 125
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hikma Pharmaceuticals Plc HIK-Financial and Strategic SWOT Analysis Review

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hikma Pharmaceuticals Plc HIK-Financial and Strategic SWOT Analysis Review



Executive Summary

Hikma Pharmaceuticals Plc (HIK)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma Pharmaceuticals) is a pharmaceutical company which undertakes the development, manufacturing and marketing of branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular and diabetes, central nervous system, oncology, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals markets its products across Europe, the US, the Middle East and North Africa region. It has manufacturing facilities in the US, Portugal, Germany, Jordan, Algeria, Saudi Arabia, Egypt, Tunisia and Morocco. Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Mar 16, 2016: Hikma Pharmaceuticals Preliminary Results

Feb 22, 2016: Hikma Appoints John Castellani to Board of Directors

Dec 03, 2015: Hikma awarded Best Company in an Emerging Market

Nov 25, 2015: Hikma announces sale of Ben Venue manufacturing facilities to Xellia Pharmaceuticals

Nov 18, 2015: Hikma announces successful resolution to FDA Warning Letter at its Portugal facility

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Hikma Pharmaceuticals Plc-Key Facts 6

Hikma Pharmaceuticals Plc-Key Employees 7

Hikma Pharmaceuticals Plc-Key Employee Biographies 8

Hikma Pharmaceuticals Plc-Major Products and Services 9

Hikma Pharmaceuticals Plc-History 10

Hikma Pharmaceuticals Plc-Company Statement 15

Hikma Pharmaceuticals Plc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Joint Venture 19

Section 2-Company Analysis 20

Hikma Pharmaceuticals Plc-Business Description 20

Hikma Pharmaceuticals Plc-Corporate Strategy 21

Hikma Pharmaceuticals Plc-SWOT Analysis 22

SWOT Analysis-Overview 22

Hikma Pharmaceuticals Plc-Strengths 22

Strength-Core Operations: Injectables 22

Strength-Focused Research and Development Activities 22

Strength-Focus on the MENA Region 22

Strength-Strong Partners Base 22

Hikma Pharmaceuticals Plc-Weaknesses 23

Weakness-Decline in Generics Performance 23

Weakness-CGMP Violation 23

Hikma Pharmaceuticals Plc-Opportunities 24

Opportunity-Roxane Acquisition 24

Opportunity-Business Initiatives 24

Opportunity-Product Approvals and Launches 24

Hikma Pharmaceuticals Plc-Threats 25

Threat-Competitive Pressures 25

Threat-Uncertain R&D Outcomes 25

Threat-Increased Drug Scrutiny 25

Hikma Pharmaceuticals Plc-Key Competitors 26

Section 3-Company Financial Ratios 27

Financial Ratios-Capital Market Ratios 27

Financial Ratios-Annual Ratios 28

Performance Chart 30

Financial Performance 30

Financial Ratios-Interim Ratios 31

Financial Ratios-Ratio Charts 32

Section 4-Company's Lifesciences Financial Deals and Alliances 33

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 34

Hikma Pharmaceuticals Plc, Recent Deals Summary 35

Section 5-Company's Recent Developments 36

Mar 16, 2016: Hikma Pharmaceuticals Preliminary Results 36

Feb 22, 2016: Hikma Appoints John Castellani to Board of Directors 41

Nov 25, 2015: Hikma announces sale of Ben Venue manufacturing facilities to Xellia Pharmaceuticals 42

Nov 18, 2015: Hikma announces successful resolution to FDA Warning Letter at its Portugal facility 43

Oct 18, 2015: Hikma renews Partnership with INJAZ for Youth Programs 44

Aug 19, 2015: Hikma Pharmaceuticals Interim Results 45

Jul 05, 2015: Hikma Pharmaceuticals supports the free Open Days at the Children's Museum Jordan 46

Jun 26, 2015: Hikma appoints Kofi Amegashie to head its sub-Saharan Africa unit 47

May 18, 2015: Hikma Founder and Honorary Life President Samih Darwazah passes away 48

Mar 11, 2015: Hikma delivers an excellent performance in 2014 with Group revenue growth of 9% and basic EPS up 30% 49

Section 6-Appendix 50

Methodology 50

Ratio Definitions 50

About GlobalData 54

Contact Us 54

Disclaimer 54

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Hikma Pharmaceuticals Plc, Performance Chart (2011-2015) 30

Hikma Pharmaceuticals Plc, Ratio Charts 32

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 34

List of Tables

Hikma Pharmaceuticals Plc, Key Facts 6

Hikma Pharmaceuticals Plc, Key Employees 7

Hikma Pharmaceuticals Plc, Key Employee Biographies 8

Hikma Pharmaceuticals Plc, Major Products and Services 9

Hikma Pharmaceuticals Plc, History 10

Hikma Pharmaceuticals Plc, Subsidiaries 17

Hikma Pharmaceuticals Plc, Joint Venture 19

Hikma Pharmaceuticals Plc, Key Competitors 26

Hikma Pharmaceuticals Plc, Ratios based on current share price 27

Hikma Pharmaceuticals Plc, Annual Ratios 28

Hikma Pharmaceuticals Plc, Interim Ratios 31

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 34

Hikma Pharmaceuticals Plc, Recent Deals Summary 35

Currency Codes 50

Capital Market Ratios 50

Equity Ratios 51

Profitability Ratios 51

Cost Ratios 52

Liquidity Ratios 52

Leverage Ratios 53

Efficiency Ratios 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Teva Pharmaceutical Industries Ltd.

SkyePharma Plc

Novartis Pharmaceuticals UK Limited

Napp Pharmaceuticals Limited

Lannett Company, Inc.

Hikma Pharmaceuticals Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand